Health-Related Quality of Life and Patient-Reported Outcomes in Radiation Oncology Clinical Trials
- PDF / 379,296 Bytes
- 16 Pages / 595.276 x 790.866 pts Page_size
- 14 Downloads / 206 Views
Palliative and Supportive Care (MP Davis, Section Editor)
Health-Related Quality of Life and Patient-Reported Outcomes in Radiation Oncology Clinical Trials Jill S. Remick, MD1 Emily Kowalski, MD1 Santanu Samanta, MD1 Sung Choi, BS2 Joshua D. Palmer, MD3 Mark V. Mishra, MD1,4,* Address *,1 Department of Radiation Oncology, University of Maryland Medical Center, 22 S. Greene Street, Baltimore, MD, 21201, USA Email: [email protected] 2 University of Maryland School of Medicine, Baltimore, MD, USA 3 Department of Radiation Oncology, The Ohio State University, Columbus, OH, USA 4 Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD, USA
* Springer Science+Business Media, LLC, part of Springer Nature 2020
This article is part of the Topical Collection on Palliative and Supportive Care Keywords Quality of life I Patient-reported outcomes I Survivorship I Radiation oncology I Patient-centered outcomes
Opinion statement The importance of assessing health-related quality of life (HRQoL) and patient-reported outcomes (PROs) is now well recognized as an essential measure when evaluating the effectiveness of new cancer therapies. Quality of life measures provide for a multidimensional understanding of the impact of cancer treatment on measures ranging from functional, psychological, and social aspects of a patient’s health. Patient-reported outcomes provide for an assessment of physical and functional symptoms that are directly elicited from patients. Collection of PROs and HRQoL data has been shown to not only be feasible but also provide for reliable measures that correlate with established outcomes measures better than clinician-scored toxicities. The importance of HRQoL measures has been emphasized by both patients and clinicians, as well as policy makers and regulatory bodies. Given the benefits associated with measuring HRQoL and PROs in oncology clinical
87
Page 2 of 16
Curr. Treat. Options in Oncol.
(2020) 21:87
trials, it is increasingly important to establish methods to effectively incorporate PROs and HRQoL measures into routine clinical practice.
Introduction The efficacy of cancer therapies has historically been measured by disease-specific outcomes such as tumor response, disease-free intervals, and overall survival. As cancer therapy has improved, the number of patients cured from or living with their cancer has dramatically increased [1]. As a result, the long-term impact of cancer therapies on a patient’s health and overall well-being has become equally as important. Health-related quality of life (HRQoL) is a comprehensive patient assessment that encompasses functional, psychological, and social aspects of an individual’s health [2]. National and international cancer research organizations now recognize HRQoL as a critical component in assessing the efficacy of cancer therapies and have made significant efforts to integrate these endpoints into clinical trials [3, 4]. Patient-reported outcomes (PROs) refer to any healthrelated information that is obtained directl
Data Loading...
